Bioequivalence, Healthy Subjects
Conditions
Keywords
bioequivalence, etoricoxib, healthy subjects, pharmacokinetics
Brief summary
The present study is a comparative bioavailability study performed to assess bioequivalence between a Test medication (Exib 120 mg etoricoxib film-coated tablets manufactured by PrJSC Pharmaceutical firm Darnitsa \[Ukraine\]) and a Reference medication (marketed medicinal product Arcoxia® 120 mg etoricoxib film-coated tablets, Marketing Authorisation Holder: UAB Merck Sharp&Dohme, Lithuania) in healthy volunteers.
Interventions
DRUGExib 120 mg etoricoxib film-coated tablets
Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
DRUGArcoxia® 120 mg etoricoxib film-coated tablets
Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
Sponsors
Anapharm
Darnitsa Pharmaceutical Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Two-period, two-sequence, two-way crossover single dose study
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Caucasian males. 2. Subjects aged between 18 and 55 years (inclusively) at the date of signing ICF which was defined as the beginning of the screening period. 3. Subjects with a BMI at screening within 18.5 to 30.0 kg/m2, inclusively. 4. Willingness to adhere to the protocol requirements and to provide written, personally signed, and dated ICF to participate in the study before the start of any study-related procedures. 5. Availability for the entire duration of the study. 6. Motivated subjects with absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee. 7. Satisfactory medical assessment at screening with no clinically relevant abnormalities as determined by medical history, physical examination, ECG, and clinical laboratory evaluation (haematology, biochemistry and urinalysis) that were reasonably likely to interfere with the subject's participation in or ability to complete the study as assessed by the Investigator. 8. Subjects were required to agree to abstain from xanthine-containing products (i.e. coffee, tea, cola, energy drinks, chocolate, etc.) from 48 hours prior to the first study drug administration until the end of confinement. 9. Subjects were required to agree to abstain from poppy seed-containing products from 48 hours prior to the first study drug administration until the end of confinement. 10. Subjects were required to agree to abstain from alcohol from 48 hours prior to the first study drug administration until the end of study. 11. Subjects were required to abstain and agree to continue to abstain from St John's Wort, vitamins and herbal remedies from 2 weeks prior to the first study drug administration until the end of confinement. 12. Subjects were required to abstain and agree to continue to abstain from beverages or food containing orange, grapefruit or pomelo from 2 weeks prior to the first study drug administration until the end of confinement. 13. Subjects had to agree to use medically acceptable methods of contraception during the study and for 30 days after the end of the study. Medically acceptable methods of contraception included using a condom with a female partner of childbearing potential who is using oral contraceptives, hormonal patch, implant or injection, intrauterine device, or diaphragm with spermicide. Complete abstinence alone could be used as a method of contraception.
Exclusion criteria
1. History of significant hypersensitivity to etoricoxib or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (such as angioedema) to any drug. 2. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. 3. History of major surgery of the gastrointestinal tract except for appendectomy. 4. History of significant gastrointestinal, liver or kidney disease that might affect the drug BA. 5. Presence of significant cardiovascular, respiratory, genitourinary, musculoskeletal, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease. 6. Presence of respiratory infection symptoms (COVID-19 infection symptoms) like fever, dry cough, nasal congestion or sore throat. 7. Having COVID-19 infection or having been in contact to people with known COVID-19 infection in the last 14 days. 8. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within 6 months prior to Day 1 Period 1. 9. History of controlled or uncontrolled hypertension or clinically relevant Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and/or Heart Rate (HR) readings outside the normal ranges at screening (Day -3) or prior to drug administration on Day 1 Period 1. Normal ranges are defined below: * SBP: 90 to 140 mmHg * DBP: 60 to 90 mmHg * HR: 50 to 100 beats/min 10. Forehead body temperature readings outside the range of 35.5 to 37.4 ºC at screening (Day -5, -4, -3, -2, -1) or prior to the first drug administration. 11. Any planned surgery involving general, spinal or epidural anaesthesia from 3 months prior to Day 1 Period 1 to 7 days after last dosing. 12. Known presence of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption. 13. Any clinically significant illness within 30 days prior to Day 1 Period 1. 14. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and Human Immunodeficiency Virus (HIV) antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampicin) within 30 days prior to Day 1 Period 1. 15. Use of Over the Counter (OTC) medications within 7 days prior to Day 1 Period 1. It was specifically reminded that this included cold preparations, Acetylsalicylic Acid (ASA), natural products used for therapeutic benefits and antacid preparations. 16. Intake of any prescription medication within 30 days prior to Day 1 Period 1. 17. Maintenance therapy with any drug or significant history of drug dependency. 18. Alcohol abuse, i.e. regular use of more than 10 units per week (one unit of alcohol equals 250 mL of beer, 125 mL of wine or 25 mL of spirits), a history of alcoholism or recovered alcoholics. 19. Positive alcohol, drugs of abuse or cotinine results at screening (Day -1). 20. Positive result on Day -5 and/or Day -2 of screening on COVID-19 RT-PCR test. 21. History of drug abuse or use of illegal drugs: use of soft drugs (e.g. marihuana) within 6 months of screening or hard drugs (e.g. amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opioids) within 1 year of screening. 22. A positive Human Immunodeficiency Virus antibody (HIV-Ab) screen, Hepatitis B surface antigen (HBsAg) or Hepatitis C Virus (HCV) tests. 23. Use of an investigational product within 60 days prior to Day 1 Period 1 or active enrolment in another drug or vaccine clinical study. 24. Use of depot injectable solutions with a half-life of \>1 week within 6 months prior to Day 1 Period 1. 25. Subjects previously randomised in this study. 26. An inability to follow a standardised diet and meal schedule or inability to fast, as required during the study. 27. Donation of blood (at least 100 mL) or plasma by plasmapheresis within 30 days prior to Day 1 Period 1. 28. Volunteers who reported difficulty swallowing tablets as a whole.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose. | The Cmax values are based on the etoricoxib plasma concentration. |
| Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) | Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose. | The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the etoricoxib plasma concentration. |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Exib (Test) First Exib 120 mg etoricoxib film-coated tablets (test product) dosed in first period followed by Arcoxia 120 mg etoricoxib film-coated tablets (reference product) dosed in the second period. | 14 |
| Arcoxia® (Reference) First Arcoxia 120 mg etoricoxib film-coated tablets (reference product) dosed in first period followed by Exib 120 mg etoricoxib film-coated tablets (test product) dosed in the second period. | 14 |
| Total | 28 |
Baseline characteristics
| Characteristic | Exib (Test) First | Arcoxia® (Reference) First | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 14 Participants | 14 Participants | 28 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 14 Participants | 14 Participants | 28 Participants |
| Region of Enrollment Turkey | 14 participants | 14 participants | 28 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 14 Participants | 14 Participants | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 28 |
| other Total, other adverse events | 3 / 28 | 2 / 28 |
| serious Total, serious adverse events | 0 / 28 | 0 / 28 |
Outcome results
Primary
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t)
The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the etoricoxib plasma concentration.
Time frame: Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose.
Population: All participants that completed the study had their samples analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Test (Exib) | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) | 21967.848 h*ng/mL | Standard Deviation 5570.437 |
| Reference (Arcoxia®) | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) | 22205.479 h*ng/mL | Standard Deviation 6046.728 |
90% CI: [96.97, 101.54]
Primary
Maximum Plasma Concentration (Cmax)
The Cmax values are based on the etoricoxib plasma concentration.
Time frame: Blood sampling for pharmacokinetic analysis covered up to 72 hours post-dose.
Population: All participants that completed the study had their samples analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Test (Exib) | Maximum Plasma Concentration (Cmax) | 1948.656 ng/mL | Standard Deviation 577.431 |
| Reference (Arcoxia®) | Maximum Plasma Concentration (Cmax) | 1916.300 ng/mL | Standard Deviation 602.446 |
90% CI: [94.54, 110.37]